FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034187979> ?p ?o ?g. }

• W2034187979 endingPage "480" @default.
• W2034187979 startingPage "475" @default.
• W2034187979 abstract "An 8-week, multicentre (72 sites in the US), double-blind, randomised, parallel group, forced titration study compared the antihypertensive efficacy of candesartan cilexetil and losartan. A total of 611 patients with essential hypertension (diastolic blood pressure 95 to 114 mm Hg) were randomised initially to candesartan cilexetil 16 mg once daily or losartan 50 mg once daily. After 2 weeks of randomised treatment, the doses of candesartan cilexetil and losartan were doubled to 32 mg and 100 mg once daily and continued respectively for 6 weeks. At week 8, candesartan cilexetil lowered the blood pressure (BP) at 24 h (trough), 6 h (peak) and 48 h post dose to a significantly greater extent (P < 0.05) than losartan: candesartan cilexetil lowered trough BP by 13.4/10.5 mm Hg, peak BP by 15.5/12.9 mm Hg and 48-h BP by 10.5/9.9 mm Hg compared to a reduction of trough BP by 10.1/9.1 mm Hg, peak BP by 12.0/9.5 mm Hg, and 48-h BP by 5.9/7.0 mm Hg by losartan. The responder and control rates were numerically higher in the candesartan cilexetil group, but the differences did not reach statistical significance; the responder rates were 58.8% for the candesartan cilexetil group and 52.1% for the losartan group and control rates were 49.0% for the candesartan cilexetil group and 44.6% for the losartan group. Overall, both treatment regimens were well tolerated. A total of 15 of the 611 (2.5%) patients withdrew from the study due to an adverse event, including nine (2.9%) in the candesartan cilexetil group and six (2.0%) in the losartan group. In conclusion, this forced titration study confirms that candesartan cilexetil is more effective in lowering BP than losartan when compared at once daily maximum doses." @default.
• W2034187979 created "2016-06-24" @default.
• W2034187979 creator A5016821981 @default.
• W2034187979 creator A5021382142 @default.
• W2034187979 creator A5025889935 @default.
• W2034187979 creator A5035540327 @default.
• W2034187979 creator A5036883976 @default.
• W2034187979 creator A5043352489 @default.
• W2034187979 creator A5054753419 @default.
• W2034187979 creator A5060165818 @default.
• W2034187979 date "2001-07-01" @default.
• W2034187979 modified "2023-09-27" @default.
• W2034187979 title "A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II" @default.
• W2034187979 cites W1996228728 @default.
• W2034187979 cites W2002177761 @default.
• W2034187979 cites W2020304135 @default.
• W2034187979 cites W2048902899 @default.
• W2034187979 cites W2054479029 @default.
• W2034187979 cites W2096841308 @default.
• W2034187979 cites W2097712021 @default.
• W2034187979 cites W2144335239 @default.
• W2034187979 cites W2588341002 @default.
• W2034187979 cites W3145527833 @default.
• W2034187979 doi "https://doi.org/10.1038/sj.jhh.1001205" @default.
• W2034187979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11464257" @default.
• W2034187979 hasPublicationYear "2001" @default.
• W2034187979 type Work @default.
• W2034187979 sameAs 2034187979 @default.
• W2034187979 citedByCount "49" @default.
• W2034187979 countsByYear W20341879792013 @default.
• W2034187979 countsByYear W20341879792014 @default.
• W2034187979 countsByYear W20341879792021 @default.
• W2034187979 countsByYear W20341879792022 @default.
• W2034187979 crossrefType "journal-article" @default.
• W2034187979 hasAuthorship W2034187979A5016821981 @default.
• W2034187979 hasAuthorship W2034187979A5021382142 @default.
• W2034187979 hasAuthorship W2034187979A5025889935 @default.
• W2034187979 hasAuthorship W2034187979A5035540327 @default.
• W2034187979 hasAuthorship W2034187979A5036883976 @default.
• W2034187979 hasAuthorship W2034187979A5043352489 @default.
• W2034187979 hasAuthorship W2034187979A5054753419 @default.
• W2034187979 hasAuthorship W2034187979A5060165818 @default.
• W2034187979 hasBestOaLocation W20341879791 @default.
• W2034187979 hasConcept C126322002 @default.
• W2034187979 hasConcept C126894567 @default.
• W2034187979 hasConcept C2780036600 @default.
• W2034187979 hasConcept C2780288358 @default.
• W2034187979 hasConcept C2908929049 @default.
• W2034187979 hasConcept C71924100 @default.
• W2034187979 hasConcept C84393581 @default.
• W2034187979 hasConcept C98274493 @default.
• W2034187979 hasConceptScore W2034187979C126322002 @default.
• W2034187979 hasConceptScore W2034187979C126894567 @default.
• W2034187979 hasConceptScore W2034187979C2780036600 @default.
• W2034187979 hasConceptScore W2034187979C2780288358 @default.
• W2034187979 hasConceptScore W2034187979C2908929049 @default.
• W2034187979 hasConceptScore W2034187979C71924100 @default.
• W2034187979 hasConceptScore W2034187979C84393581 @default.
• W2034187979 hasConceptScore W2034187979C98274493 @default.
• W2034187979 hasIssue "7" @default.
• W2034187979 hasLocation W20341879791 @default.
• W2034187979 hasLocation W20341879792 @default.
• W2034187979 hasOpenAccess W2034187979 @default.
• W2034187979 hasPrimaryLocation W20341879791 @default.
• W2034187979 hasRelatedWork W1865937959 @default.
• W2034187979 hasRelatedWork W1965521882 @default.
• W2034187979 hasRelatedWork W2044256491 @default.
• W2034187979 hasRelatedWork W2064163113 @default.
• W2034187979 hasRelatedWork W2065811410 @default.
• W2034187979 hasRelatedWork W2127324952 @default.
• W2034187979 hasRelatedWork W2165093592 @default.
• W2034187979 hasRelatedWork W2171797634 @default.
• W2034187979 hasRelatedWork W2335417257 @default.
• W2034187979 hasRelatedWork W2470013167 @default.
• W2034187979 hasVolume "15" @default.
• W2034187979 isParatext "false" @default.
• W2034187979 isRetracted "false" @default.
• W2034187979 magId "2034187979" @default.
• W2034187979 workType "article" @default.